REMARKS/ARGUMENTS

Claims 12-16 have been amended. Support for the amendment is found at

specification page 7, paragraph [0011] and in original Claim 12. No new matter has been

added.

Applicants thank the Examiner for the indication of allowable subject matter in

Claims 1-11 and 16-22.

The rejection of Claims 12-15 under 35 U.S.C. 102(b) as being anticipated by Kazuya

et al (JP 05027430) is traversed. The Office has indicated that Compound (9) of Kazuya

anticipates formula (2). In response, formula (2) has been deleted from Claim 12.

Furthermore, Kazuya does not suggest or disclose any compounds of remaining formulas (3)

to (8). The rejection should be withdrawn.

Consequently, in view of the present amendment, no further issues are believed to be

outstanding in the present application, and the present application is believed to be in

condition for formal allowance. An early and favorable action is therefore respectfully

requested.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,

MAIER & NEUSTADT, L.L.P.

Norman F. Oblon

Customer Number

22850

Tel: (703) 413-3000 Fax: (703) 413 -2220

(OSMMN 08/09)

Soonwuk Cheong

Registration No. 62,793

15